Trial Profile
A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PrTK03
- Sponsors Advantagene; Candel Therapeutics
- 04 Apr 2024 According to a Candel Therapeutics media release, this pivotal phase 3 clinical trial is being conducted under a Special Protocol Assessment by FDA.
- 30 Mar 2023 According to a Candel Therapeutics media release, topline data is expected in the fourth quarter of 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2024.